Archive

Abstract

Stones refer to solid mineral and crystalline deposits that form within the urinary system, including the kidneys, ureters, bladder, and urethra. These stones are composed of various minerals and can range in size from small particles to larger, more obstructive structures. These guidelines serve as a valuable resource for healthcare professionals in understanding the epidemiology and recommended management strategies for distal ureteric stones. The main etiological factors are Urinary tract infections, Certain medical conditions, Anatomical factors. Signs and symptoms are Flank pain , Hematuria Dysuria,Urinary urgency, frequency, Nausea and vomiting. Diagnostic tests like Non-contrast Computed Tomography (CT), Intravenous Pyelogram (IVP), Ultrasonography (US), Retrograde Ureterography, Management like Extracorporeal Shock Wave Lithotripsy (ESWL), Ureteroscopy, Percutaneous Nephrolithotomy (PCNL), Alpha-blockers, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics. Pharmacodynamics of tamsulosin is the relaxation of smooth muscle in the ureter, which is achieved through the blockade of alpha-1 adrenergic receptors. Tamsulosin is well absorbed, protein binding of approximately 99%, eliminated mainly via hepatic metabolism, with less than 1% of the dose excreted unchanged in the urine. Adverse effects of tamsulosin Intraoperative floppy iris syndrome (IFIS) , Abnormal ejaculation and retrograde ejaculation, Dizziness and postural hypotension. Pharmacodynamics of silodosin in ureteric stones is believed to involve the relaxation of smooth muscle in the ureter, which promotes stone passage. Silodosin is wellabsorbed, moderate volume of distribution eliminated mainly via hepatic metabolism, with less than 1% of the dose excreted unchanged in the urine.

Keywords

Tamsulosin, silodosin, Non-contrast Computed Tomography (CT), Intravenous Pyelogram (IVP), Ultrasonography (US), Retrograde Ureterography, Management like Extracorporeal Shock Wave Lithotripsy (ESWL), Ureteroscopy, Percutaneous Nephrolithotomy (PCNL), Alpha-blockers, Drugs (NSAIDs), Analgesics

Reference

  1. Türk C, N. A. EAU Guidelines on Urolithiasis. European Association of Urolog. 2021. 
  2. Abrams P, et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Pharmacother. 2011;12(17):2739-2748. 
  3. Chang DF, Chen J. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664-673. 
  4. Dellabella M, et al. Silodosin facilitates the passage of distal ureteral stones. Urology. 2010 Mar;75(3):485-9. 
  5. Fovargue D, et al. Silodosin: a new alpha-blocker for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2010;67(13):1079-1085. 
  6. Furyk JS, et al. Distal Ureteric Stones and Tamsulosin: A Double-Blind, PlaceboControlled, Randomized, Multicenter Trial. Ann Emerg Med. 2016;67(1):86-95.e2. 
  7. Fwu CW, et al. Emergency Department Visits, Use of Imaging, and Drugs for Urolithiasis Have Increased in the United States. Kidney Int. 2013;83(3):479-486. 
  8. Gacci M, et al. Meta-analysis of the efficacy and safety of silodosin in the treatment of male lower urinary tract symptoms. Urology. 2012;79(6):1290-1297. 
  9. Goldfarb DS, et al. Medical Management of Kidney Stones: AUA Guideline. J Urol. 2014;192(2):316-324. 
  10. Hänseler E, et al. Clinical pharmacokinetics of silodosin. Clin Pharmacokinet. 2012;51(6):391-403. 
  11. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev. 2015;(7):CD004137. 
  12. Hollingsworth JM, Canales BK. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. 
  13. J MC. Change in epidemiologic features of urolithiasis in the United States over the last three decades: a population-based study. J Urol. 2011;186(5):1772-1776. 
  14. Lepor H, et al. Tamsulosin: preclinical evidence for selectivity to the human seminal vesicles. J Urol. 1997;157(3):1191-1194. 
  15. MC M. Pharmacology and clinical use of silodosin for the treatment of benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):483.
  16. McVary KT, et al. Silodosin in men with signs and symptoms of benign prostatic hyperplasia: results of a phase III, placebo-controlled, multicenter trial. Urology. 2007;70(6):1111-1116. 
  17. Moore CL, et al. Imaging in Suspected Renal Colic: Systematic Review of the Literature and Multispecialty Consensus. Ann Emerg Med. 2019;74(3):391-402. 
  18. Pearle MS, et al. Medical management of kidney stones: AUA guideline. American Urological Association. 2014. 
  19. Porpiglia F, et al. Silodosin for medical expulsive therapy in ureteral calculi: randomized, double-blind, placebo-controlled study. Urology. 2010;75(6):1275-1280.
  20. Preminger GM, et al. Guideline for the management of ureteral calculi. Eur Urol. 2007;52(6):1610-1631. 
  21. Roehrborn CG, et al. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2002;59(4):428-433. 
  22. Roehrborn CG, van Kerrebroeck P. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92(3):257-261. 
  23. Romero V, et al. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-e96. 
  24. Salem EA, et al. Tamsulosin hydrochloride: pharmacokinetics and pharmacodynamics in patients with normal and impaired renal function. J Urol. 1999;161(5):1598-1602. 
  25. Scales CD Jr, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. 
  26. Seitz C, et al. Medical expulsive therapy of ureteral colic with silodosin: a randomized controlled study. World J Urol. 2013;31(6):1565-1570. 
  27. Smith-Bindman R, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100-1110. 
  28. Stamatelou KK, Francis ME. Time trends in the reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817-1823.
  29. Takasu T, et al. Silodosin: a selective alpha1A-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2009;10(16):2619-2631. 
  30. Tanaka ST, et al. Evaluation and management of pediatric urolithiasis: AUA guideline. J Urol. 2021;206(4):970-978. 
  31. Türk C, K. T. Guidelines on Urolithiasis. European Association of Urology. 2020.
  32. Türk C, N. A. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol. 2021;80(6):704-718.
  33. Xiong T, et al. Efficacy of silodosin in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis. Urolithiasis. 2017;45(5):507-515. 
  34. Yamaguchi O, et al. Silodosin in the treatment of lower urinary tract symptoms. Expert Opin Pharmacother. 2012;13(17):2529-2537. 
  35. Yan H, Zhu G. Epidemiology and management of urinary stones in pregnant women: a literature review. Urolithiasis. 2018;46(6):553-5

Photo
Y. Bhavana
Corresponding author

Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India.

Photo
T. Bhavana
Co-author

Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India.

Photo
S. D. Reshma
Co-author

Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India.

Photo
S. Balakrishna Reddy
Co-author

Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India.

Photo
Dr. M. Lakshmi Banusri
Co-author

Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India.

Y. Bhavana*, T. Bhavana, S. D. Reshma, S. Balakrishna Reddy, Dr. M. Lakshmi Banusri, Tamsulosin Versus Silodosin for The Treatment of Distal Ureteric Stones: A Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 96-103. https://doi.org/10.5281/zenodo.8246283

More related articles
Review On Mouth Dissolving Film: The Advancement I...
Sakshi D. Patil, Shubhangi S. Ambekar, Sandip A. Tadavi, Sunil P....
UV Visible Spectroscopic And FTIR Analysis of Aana...
Selvamani S., Justus Antony. S, Manoharan. A, ...
A Microsponge-Based Drug Delivery System For The T...
Shivani Soni, Dharmesh Sisodiya, Tanu Bhargava, Kamlesh Dashora,...
Niosomes Used In Treatment Of Cancer: A Review...
Sudarshan Kale, Shraddha vaishnav , Vinit khairnar , chaitali markand , ...
A Review on Formulation and Evaluation of Herbal Shampoo...
Chandraprabha Dewangan , Rishi Kumar, Harish Sharma, Gyanesh Kumar Sahu, ...
Related Articles
Formulation And Evaluation Of Transdermal Patch For Polycystic Ovary Syndrome (P...
Preeti gupta , Nitesh Choudhary , Kajal Bokade, Aishwarya Sable, Ankita Suryavanshi, Shweta Patil , ...
An Updated Review On Dicliptera Bupleuroides: Its Phytochemicals, Medicinal Use,...
Munish Choudhary, Dev Prakash Dahiya, Dinesh Kumar Thakur, Bhopesh Kumar, ...
A New Stability Indicating UV Method Development And Validation For The Quantifi...
Gangu Sreelatha, Mahaboobi, Katta Sruthi, Meghavath Subhash, ...
Review On Mouth Dissolving Film: The Advancement In Oral Drug Delivery...
Sakshi D. Patil, Shubhangi S. Ambekar, Sandip A. Tadavi, Sunil P. Pawar, ...
More related articles
Review On Mouth Dissolving Film: The Advancement In Oral Drug Delivery...
Sakshi D. Patil, Shubhangi S. Ambekar, Sandip A. Tadavi, Sunil P. Pawar, ...
A Microsponge-Based Drug Delivery System For The Treatment Of Fungal Infection...
Shivani Soni, Dharmesh Sisodiya, Tanu Bhargava, Kamlesh Dashora, ...
Review On Mouth Dissolving Film: The Advancement In Oral Drug Delivery...
Sakshi D. Patil, Shubhangi S. Ambekar, Sandip A. Tadavi, Sunil P. Pawar, ...
A Microsponge-Based Drug Delivery System For The Treatment Of Fungal Infection...
Shivani Soni, Dharmesh Sisodiya, Tanu Bhargava, Kamlesh Dashora, ...